923288-95-3 Usage
Description
Nilotinib hydrochloride anhydrous is a pharmaceutical compound that serves as a potent and selective tyrosine kinase inhibitor. It is primarily used in the treatment of chronic myelogenous leukemia (CML), a type of cancer that affects white blood cells. Nilotinib hydrochloride anhydrous has also gained attention in the context of COVID-19-related research, indicating its potential for broader therapeutic applications.
Uses
Used in Oncology:
Nilotinib hydrochloride anhydrous is used as an anticancer agent for the treatment of chronic myelogenous leukemia. It functions by inhibiting the activity of the BCR-ABL tyrosine kinase, which is a crucial driver of the uncontrolled cell growth observed in CML. This targeted approach helps to control the disease and improve patient outcomes.
Used in COVID-19 Research:
Nilotinib hydrochloride anhydrous is also used as a research product in the context of COVID-19. Its potential role in this area may involve modulating the immune response or targeting specific pathways relevant to the SARS-CoV-2 virus. As a COVID-19-related research product, it contributes to the ongoing efforts to understand and combat the pandemic.
Check Digit Verification of cas no
The CAS Registry Mumber 923288-95-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,2,3,2,8 and 8 respectively; the second part has 2 digits, 9 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 923288-95:
(8*9)+(7*2)+(6*3)+(5*2)+(4*8)+(3*8)+(2*9)+(1*5)=193
193 % 10 = 3
So 923288-95-3 is a valid CAS Registry Number.
923288-95-3Relevant articles and documents
Method for preparing nilotinib monohydrochloride dihydrate crystal form A
-
Paragraph 0133-0162, (2021/08/07)
The invention provides a method for preparing nilotinib monohydrochloride dihydrate crystal form A. Specifically, the method provided by the invention comprises the following steps: (1) mixing nilotinib a free alkali as shown in a formula I, hydrochloric
KINASE INHIBITOR SALTS AND COMPOSITIONS THEREOF
-
Page/Page column 91-92, (2020/01/08)
The present invention relates to kinase inhibitor C8-C16 aliphatic sulfate salts and compositions thereof.
NOVEL SALTS OF NILOTINIB AND CRYSTALLINE FORMS THEREOF
-
Paragraph 0042; 0091, (2018/05/24)
The present invention provides novel salts of Nilotinib and crystalline forms thereof. Specific salt and crystalline forms thereof provided by the present invention include Nilotinib trihydrochloride dihydrate Form APO-VIII, Nilotinib gentisate Form APO-I, Nilotinib gentisate Form APO-II, Nilotinib digentisate Form APO-III, Nilotinb dibenzoate Form APO-I, Nilotinib dilevulinate Form APO-I, Nilotinib saccharinate monohydrate Form APO-I, Nilotinib saccharinate Form APO-II, Nilotinib diglycolate Form APO-I and Nilotinib glycerophosphate Form APO-I.
